(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Aldeyra Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ALDX's revenue for 2025 to be $1,248,224,054, with the lowest ALDX revenue forecast at $1,248,224,054, and the highest ALDX revenue forecast at $1,248,224,054. On average, 3 Wall Street analysts forecast ALDX's revenue for 2026 to be $4,584,767,679, with the lowest ALDX revenue forecast at $988,277,202, and the highest ALDX revenue forecast at $9,583,294,080.
In 2027, ALDX is forecast to generate $3,973,233,726 in revenue, with the lowest revenue forecast at $2,401,813,079 and the highest revenue forecast at $6,493,280,695.